The emergence of a new treatment, which broke the one-year barrier of the survival period of cancer patients

A lung cancer treatment, which extended the survivalperiod of inexperienced patients to an epoch-making time, will enter the Korean market.

The product has received attention because it broke the one-year barrier in the survival period of lung cancer patients.

According to the Ministry of Food and Drug Safety on the 13^th, Novartis was approved to sell the ALK (anaplastic lymphoma kinase) non-...